Cargando…

Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report

Psoriasis is an immune-mediated chronic inflammatory dermatosis influenced by hereditary and environmental factors. Human immunodeficiency virus (HIV) infection affects the immune system and exacerbates psoriatic lesions. We report the case of a 33-year-old male patient diagnosed with psoriasis vulg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Jian, Wu, Weiwei, Qiu, Liguo, Wang, Xi, Bao, Jianwei, Wang, Jinjing, Cheng, Lifang, Fu, Zhiyuan, Hu, Fengming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809383/ https://www.ncbi.nlm.nih.gov/pubmed/36605452 http://dx.doi.org/10.2147/CCID.S395348

Ejemplares similares

Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis
por: Godse, Kiran
Publicado: (2017)

Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis
por: Rongioletti, Franco, et al.
Publicado: (2018)

Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
por: Frustaci, Andrea, et al.
Publicado: (2023)

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
por: Eshwar, Vishnu, et al.
Publicado: (2022)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Control of porphyria cutanea tarda with anti-IL-17 secukinumab in a person with psoriasis living with HIV
por: Bedier, Helbies, et al.
Publicado: (2023)

Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective
por: Johar, Asmah, et al.
Publicado: (2019)

Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016)

Profile of secukinumab in the treatment of psoriasis: current perspectives
por: Roman, Michael, et al.
Publicado: (2015)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
por: Yang, Eric J, et al.
Publicado: (2018)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Refractory Psoriasis Vulgaris with Itching Successfully Treated with the Anti-interleukin-17A Antibody Secukinumab: A Case of Secondary Failure of Other Biologic Agents
por: Kurosaki, Yuko, et al.
Publicado: (2017)

Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
por: Picciani, Bruna Lavinas Sayed, et al.
Publicado: (2021)

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report
por: Lu, Xujun, et al.
Publicado: (2023)

Identification immune response genes in psoriasis after treatment with secukinumab
por: Wang, Jing, et al.
Publicado: (2023)

Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)

Interleukin-17A and Keratinocytes in Psoriasis
por: Furue, Masutaka, et al.
Publicado: (2020)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Secukinumab for psoriasis in a patient with familial Mediterranean fever
por: Cannavò, Serafinella P., et al.
Publicado: (2019)

Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
por: Tiberio, Rossana, et al.
Publicado: (2019)

Behandlung der Psoriasis mit Secukinumab: Praxisrelevante Hinweise
por: Körber, Andreas, et al.
Publicado: (2021)

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
por: Narbutt, Joanna, et al.
Publicado: (2023)

Real-world investigation of the efficacy and safety of secukinumab for psoriasis treatment in a Chinese population
por: Zeng, Jing-Xin, et al.
Publicado: (2021)

Association of genetic polymorphism of interleukin-17A & interleukin-17F with susceptibility of psoriasis
por: Kaur, Rajinder, et al.
Publicado: (2018)

A Case of Moderate Hidradenitis Suppurativa and Psoriasis Treated with Secukinumab
por: Giuseppe, Pistone, et al.
Publicado: (2018)

Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2017)

Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients
por: Gerdes, S., et al.
Publicado: (2019)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis
por: Mendes Roncada, Eduardo V., et al.
Publicado: (2021)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Secukinumab for the treatment of generalized pustular psoriasis: A case report
por: Li, Jiayan, et al.
Publicado: (2023)

Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
por: Choi, Esther, et al.
Publicado: (2023)

Progression of Pre-Existing Vitiligo during Secukinumab Treatment for Psoriasis
por: Kim, Jin Cheol, et al.
Publicado: (2023)

Case report: Successful treatment of acute generalized pustular psoriasis of puerperium with secukinumab
por: Xue, Gao, et al.
Publicado: (2022)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab
por: Malakouti, Mona, et al.
Publicado: (2016)

Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis
por: Neema, Shekhar, et al.
Publicado: (2019)

Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date
por: Kivelevitch, Dario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7guon5ef82dhcffq14t1kq4bvh